^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    neoantigen DNA vaccine

    i
    Other names: neoantigen DNA vaccine
    Associations

    News

    Trials
    Company:
    AstraZeneca, Washington University School of Medicine in St. Louis
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=7, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    neoantigen DNA vaccine
    7ms
    Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=7, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2030 --> Dec 2030 | Trial primary completion date: Oct 2028 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    neoantigen DNA vaccine
    8ms
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    9ms
    Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=7, Not yet recruiting, Washington University School of Medicine | N=10 --> 7
    Enrollment change
    |
    neoantigen DNA vaccine
    9ms
    Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jul 2028 --> Sep 2030 | Trial primary completion date: Aug 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    neoantigen DNA vaccine
    11ms
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=18, Terminated, Washington University School of Medicine | Trial completion date: Aug 2023 --> May 2023 | Active, not recruiting --> Terminated; Drugs/equipment unavailable and insufficient funding
    Trial completion date • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    12ms
    Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2028 --> Jul 2028 | Trial primary completion date: May 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    neoantigen DNA vaccine
    1year
    Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation • MGMT promoter methylation • IDH wild-type
    |
    Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
    over1year
    Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jun 2027 --> Oct 2027 | Initiation date: Jun 2023 --> Oct 2023 | Trial primary completion date: Sep 2024 --> Jan 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation • MGMT promoter methylation • IDH wild-type
    |
    Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
    over1year
    Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=27, Recruiting, Washington University School of Medicine | Trial completion date: Jun 2026 --> Mar 2030 | Trial primary completion date: Jun 2024 --> Mar 2028
    Trial completion date • Trial primary completion date • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • neoantigen DNA vaccine
    over1year
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Trial completion date: Apr 2023 --> Dec 2023
    Trial completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over1year
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Washington University School of Medicine | Trial completion date: Feb 2023 --> Aug 2023
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    over1year
    Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine
    New P1 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation • MGMT promoter methylation • IDH wild-type
    |
    Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
    almost2years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Washington University School of Medicine | Trial completion date: Aug 2023 --> Feb 2023
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    2years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> May 2022
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    2years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Aug 2023
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    over2years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over2years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    almost3years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    almost3years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=13, Recruiting, Washington University School of Medicine | Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    almost3years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Washington University School of Medicine | N=10 --> 13
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    over3years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Jul 2024 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Aug 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over3years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=24 --> 10 | Trial completion date: Dec 2023 --> Dec 2022 | Trial primary completion date: Oct 2022 --> Jan 2022
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    over4years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington University School of Medicine | Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Oct 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    over4years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=6, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over4years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2024 --> Aug 2024 | Initiation date: Apr 2020 --> Aug 2020 | Trial primary completion date: Jul 2023 --> Nov 2023
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over4years
    Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington University School of Medicine | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Sep 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • neoantigen DNA vaccine
    almost5years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Mar 2024 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2023 --> Jun 2023
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine